Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, primarily caused by smoking and air pollution. These factors lead to lung cell damage, resulting in irreversible chronic inflammation, which significantly impacts patients' quality of life and life expectancy. However, current treatments only alleviate symptoms and cannot effectively predict disease progression or provide a fundamental cure.
A research team led by Dr. Jiu-Yao Wang, Director of CMU Children's Hospital, has successfully developed a novel diagnostic and therapeutic technology based on Surfactant Protein D (SP-D). This technology not only uses genetic analysis to predict the development risk of COPD but also improves lung inflammation through recombinant protein technology, offering new hope for millions of patients worldwide.
SP-D Technology Breakthrough: Accurate Diagnosis and Innovative Treatment
Currently, COPD diagnosis mainly relies on medical history, pulmonary function tests, and imaging assessments, with no effective tools to predict the progression of the disease. The core advantage of this technology lies in its combination of diagnosis and treatment, providing physicians with more precise clinical decision-making support.
The research found that SP-D plays a key role in the lung immune system, where it can bind to microorganisms and allergens and regulate macrophage inflammatory responses. Through genetic analysis, the susceptibility and prognosis of COPD patients can be predicted, guiding personalized treatment strategies. The study further confirmed that SP-D gene polymorphism is closely related to the risk, severity, and prognosis of COPD. More importantly, in animal experiments, mice with SP-D gene deficiency exhibited COPD-related symptoms, which were significantly improved after recombinant SP-D protein treatment, with foam-like macrophages returning to normal. This discovery offers a new direction for the diagnosis and treatment of COPD. In the future, this technology may further develop into a protein drug, expanding to global markets. The technology has been published in the prestigious journal Cellular and Molecular Immunology and has received patents in Taiwan and the United States, demonstrating its innovative value in precision medicine.
Technology Development Prospects: Expert Interviews and Future Plans
Dr. Jiu-Yao Wang stated that the team's research has confirmed the close relationship between SP-D gene polymorphism and the risk and prognosis of COPD. Recombinant SP-D protein is expected to become a new therapeutic option. This technology not only improves the accuracy of current diagnostic methods but also offers personalized treatment for patients, enhancing survival rates and quality of life. In the future, the team will actively promote the clinical application of SP-D diagnostic and therapeutic technology, collaborating with the international pharmaceutical industry to accelerate regulatory review and market entry. The team plans to first target the diagnostic market and use a business model to support the development of protein drugs, with the ultimate goal of launching a new COPD nasal spray. As the era of precision medicine arrives, the development of SP-D technology will provide revolutionary diagnostic and therapeutic solutions for COPD patients worldwide.
Resource: 重組肺泡表面蛋白D 顯著改善阻塞性肺病發炎
